Given the increased ADAM33 expression in smooth muscle cells in atherosclerosis [6] and following our hypothesis that overexpression of ADAM33 may lead to the pathological events, subjects at risk may receive tailored therapy with a special target on ADAM33 levels or activity. The gene discussed is ADAM33; the disease is atherosclerosis.